Supreme Court rejects Allergan patent appeal over Sanctura

Mon Oct 15, 2012 10:22am EDT

Related Topics

(Reuters) - The U.S. Supreme Court rejected on Monday Allergan Inc's appeal of a ruling that favored generic drugmaker Watson Pharmaceuticals Inc over patents related to the treatment of an overactive bladder.

Allergan was challenging a June decision by the U.S. Federal Circuit Court of Appeals that its patents related to Sanctura XR were invalid because the treatment was "obvious," meaning it was highly likely to succeed based on information already known.

(Reporting By Terry Baynes and Jon Stempel in New York; Editing by Howard Goller and Gerald E. McCormick)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.